Astellas Pharma (JP:4503) has released an update.
Astellas Pharma’s PADCEV, in combination with KEYTRUDA, has received a positive CHMP opinion for first-line treatment of advanced bladder cancer, potentially doubling the median overall survival rate compared to current chemotherapy treatments. The opinion is based on Phase 3 trial results and has already been approved by the FDA for the same use in the United States. This treatment represents a significant advancement for patients with unresectable or metastatic urothelial cancer.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
